Aldeyra Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALDX Nasdaq 2830 www.aldeyra.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aldeyra Therapeutics, Inc.

Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? - Dec 9th, 2024 3:05 pm
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference - Dec 2nd, 2024 12:00 pm
Top US Penny Stocks To Watch In November 2024 - Nov 20th, 2024 1:06 pm
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Nov 19th, 2024 3:00 pm
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement - Nov 18th, 2024 12:00 pm
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference - Nov 14th, 2024 12:00 pm
Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year? - Nov 12th, 2024 2:40 pm
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting - Oct 31st, 2024 11:00 am
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease - Oct 3rd, 2024 11:00 am
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Sep 5th, 2024 11:00 am
High Growth Tech Stocks To Watch In The United States - Sep 4th, 2024 2:05 pm
Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory - Aug 30th, 2024 2:38 pm
Aldeyra’s Phase III clinical trial of Reproxalap meets primary endpoint - Aug 9th, 2024 10:32 am
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap - Aug 8th, 2024 11:00 am
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap - Aug 7th, 2024 8:01 pm
Owning 36% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), - Jul 31st, 2024 1:01 pm
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable - Jun 20th, 2024 11:00 am
Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial - Jun 14th, 2024 10:32 am
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease - Jun 13th, 2024 11:00 am
Aldeyra Therapeutics to Host Investor Roundtable Q&A - Jun 12th, 2024 11:00 am